Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Shenogen enters into an exclusive license with BioArdis to develop and commercialise FGFR4 kinase inhibitor for Asian market

pharmaceutical-business-reviewApril 08, 2020

Tag: Shenogen , BioArdis , BIO-1262

PharmaSources Customer Service